Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment

  1. González-Barca, E.
  2. Canales, M.
  3. Cortés, M.
  4. Vidal, M.J.
  5. Salar, A.
  6. Oriol, A.
  7. Bargay, J.
  8. Bello, J.L.
  9. Sánchez, J.J.
  10. Tomás, J.F.
  11. Donato, E.
  12. Ferrer, S.
  13. Caballero, D.
Revue:
Nuclear Medicine Communications

ISSN: 0143-3636 1473-5628

Année de publication: 2013

Volumen: 34

Número: 10

Pages: 946-952

Type: Article

DOI: 10.1097/MNM.0B013E328363C695 GOOGLE SCHOLAR

Objectifs de Développement Durable